Enzyme-Catalyzed Linker Synthesis for Targeted Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug conjugates for cancer treatment lack specificity and often cause adverse reactions due to non-targeted delivery of cytotoxic agents, necessitating the development of more effective linkers that are stable in vivo, maintain targeting moiety affinity, and facilitate controlled drug release.
Innovation Solution
A process for preparing a compound of Formula (A1) using enzyme-catalyzed reactions, involving acylating reagents and deprotection steps, to create a linker that is enantioselective and scalable, improving the stability and targeting efficiency of drug conjugates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cytotoxic chemotherapy drugs are used, then cancer treatment is provided, but lack of specificity causes injury to normal cells and serious adverse reactions
Solution Approach 1:
The drug conjugate is segmented into distinct functional components: a targeting moiety (antibody or peptide) that specifically binds to cancer cells, a linker that connects the drug to the targeting moiety, and the cytotoxic agent. This segmentation allows each component to perform its specific function independently, with the targeting moiety providing specificity and the linker providing controlled release, thereby reducing harmful effects on normal cells.
Solution Approach 2:
The linker acts as an intermediary between the targeting moiety and the cytotoxic agent. It is designed to be stable in vivo to maintain the conjugate structure during circulation, yet capable of releasing the drug at the target site. This intermediary component enables preferential delivery of the cytotoxic agent to cancer cells while minimizing exposure to normal cells, thus reducing adverse reactions.
2Manufacturing precision
If linkers are designed to be stable in vivo for drug delivery, then targeting accuracy is improved, but drug release capability may be compromised
Solution Approach 1:
The linker is designed with dynamic properties that allow it to transition from a stable state during circulation to a drug-releasing state at the target site. The linker maintains structural stability in vivo to ensure accurate targeting and circulation, but incorporates chemical or environmental triggers (such as pH changes, enzyme cleavage, or redox conditions) that enable controlled drug release once the conjugate reaches the cancer cell. This dynamic design resolves the contradiction between stability for targeting and capability for release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process enhances the yield and scalability of linker production, achieving greater than 75% enantiomeric excess, reducing adverse reactions by ensuring precise delivery of cytotoxic agents to cancer cells while maintaining targeting moiety affinity.
Implementation Method 1
treating a compound of Formula (A4) or a salt thereof, with Ak1, wherein Ak1 is an acylating reagent, in the presence of an enzyme to provide a mixture of a compound of Formula (A2) and a compound of Formula (A3)
Implementation Method 2
deprotecting the compound of Formula (A2), or a salt thereof, to provide a compound of Formula (A1), or a salt thereof
Data Source
AI summary
The present invention relates to processes for preparing linkers that are useful in the conjugation of therapeutic molecules (e.g., cytotoxic agents) with targeting moieties (e.g., proteins, peptides, antibodies, nanoparticles, nucleic acids). During said processes lipases like lipase B from Candida antarctica were used for enantioselective resolution of (S,S)-2-benzylthiocyclohexanol or (S,S)-2-benzylthiocycloheptanol in presence of acylating agent which are reduced for deprotection to yield (S,S)-2-mercaptocyclohexanol or (S,S)-2-mercaptocyclopentanol which can then be used for linking therapeutic with targeting moieties.